MX2020003538A - Aglutinante anti-adrenomedulina (adm) para ser utilizado en terapia o prevencion de sintomas de padecimientos. - Google Patents

Aglutinante anti-adrenomedulina (adm) para ser utilizado en terapia o prevencion de sintomas de padecimientos.

Info

Publication number
MX2020003538A
MX2020003538A MX2020003538A MX2020003538A MX2020003538A MX 2020003538 A MX2020003538 A MX 2020003538A MX 2020003538 A MX2020003538 A MX 2020003538A MX 2020003538 A MX2020003538 A MX 2020003538A MX 2020003538 A MX2020003538 A MX 2020003538A
Authority
MX
Mexico
Prior art keywords
adrenomedullin
adm
illness
symptoms
therapy
Prior art date
Application number
MX2020003538A
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
Adrenomed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrenomed Ag filed Critical Adrenomed Ag
Publication of MX2020003538A publication Critical patent/MX2020003538A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La materia objeto de la presente invención es un anticuerpo anti-adrenomedulina (ADM) o un fragmento de anticuerpo anti-adrenomedulina o andamio no Ig anti-ADM para ser utilizado en terapia o prevención de síntomas de padecimientos y/o para ser utilizado en terapia o prevención de enfermedades caracterizadas por dichos síntomas. Los síntomas del padecimiento se pueden seleccionar a partir 5 del grupo de náusea, cefalea, dolores musculares, dolor de espalda, temblores, vómito en un individuo en el cual dicho anticuerpo o fragmento o andamio se puede unir a ADM de los aminoácidos 1 a 52 (SEQ ID NO: 1), o a fragmentos de la misma.
MX2020003538A 2017-09-25 2018-09-25 Aglutinante anti-adrenomedulina (adm) para ser utilizado en terapia o prevencion de sintomas de padecimientos. MX2020003538A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192999 2017-09-25
EP17203370 2017-11-23
PCT/EP2018/075987 WO2019057992A2 (en) 2017-09-25 2018-09-25 ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE

Publications (1)

Publication Number Publication Date
MX2020003538A true MX2020003538A (es) 2020-07-29

Family

ID=63722372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003538A MX2020003538A (es) 2017-09-25 2018-09-25 Aglutinante anti-adrenomedulina (adm) para ser utilizado en terapia o prevencion de sintomas de padecimientos.

Country Status (12)

Country Link
US (1) US20220227854A1 (es)
EP (4) EP4159229A1 (es)
JP (1) JP7461875B2 (es)
KR (1) KR20200088302A (es)
CN (1) CN111511390A (es)
AU (2) AU2018335438A1 (es)
BR (1) BR112020005450A2 (es)
CA (1) CA3076691A1 (es)
IL (1) IL273533A (es)
MX (1) MX2020003538A (es)
SG (1) SG11202002258WA (es)
WO (1) WO2019057992A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002856A2 (pt) 2019-08-30 2022-08-09 4TEEN4 Pharmaceuticals GmbH Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
JP2023515042A (ja) * 2020-02-27 2023-04-12 アドレノメト アクチェンゲゼルシャフト ショックの治療若しくは予防において使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
CN115917325A (zh) * 2020-03-16 2023-04-04 艾德里诺医药公司 感染冠状病毒的患者中的肾上腺髓质素原或其片段以及用针对肾上腺髓质素的结合剂进行的治疗
CN111893085A (zh) * 2020-08-04 2020-11-06 北京臻溪谷医学研究中心（有限合伙） 一种通过干细胞体外分化获得人工皮肤的方法及其应用
WO2024017331A1 (zh) * 2022-07-20 2024-01-25 上海济煜医药科技有限公司 一种抗肾上腺髓质素非中和抗体、其制备方法及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1427750B1 (en) 2001-08-30 2010-12-08 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
PT2311432E (pt) 2002-06-07 2015-02-09 Dyax Corp Polipeptídeos de domínio kunitz modificado e sua utilização para a redução de isquemia ou aparecimento de uma resposta inflamatória sistémica associada a um procedimento cirúrgico
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
NZ598351A (en) 2009-08-27 2014-08-29 Covagen Ag Il-17 binding compounds and medical uses thereof
WO2011073209A1 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
TR201906295T4 (tr) 2010-06-08 2019-05-21 Astrazeneca Ab IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
SG11201402358RA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
MY174877A (en) * 2011-11-16 2020-05-20 Adrenomed Ag Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition
KR102176469B1 (ko) * 2011-11-16 2020-11-10 아드레노메드 아게 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
PL2594587T3 (pl) * 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry
JP6259905B2 (ja) * 2013-03-20 2018-01-10 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 血圧降下治療をガイドするアドレノメジュリン
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
BR112019011713A2 (pt) * 2016-12-16 2019-10-15 Adrenomed Ag anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma

Also Published As

Publication number Publication date
IL273533A (en) 2020-05-31
JP2020535151A (ja) 2020-12-03
AU2023201479A1 (en) 2023-04-13
WO2019057992A2 (en) 2019-03-28
JP7461875B2 (ja) 2024-04-04
EP3854414A1 (en) 2021-07-28
CA3076691A1 (en) 2019-03-28
WO2019057992A3 (en) 2019-05-02
US20220227854A1 (en) 2022-07-21
RU2020114429A (ru) 2021-10-27
EP3687567A2 (en) 2020-08-05
KR20200088302A (ko) 2020-07-22
BR112020005450A2 (pt) 2020-09-29
CN111511390A (zh) 2020-08-07
EP4159230A1 (en) 2023-04-05
EP4159229A1 (en) 2023-04-05
AU2018335438A1 (en) 2020-04-09
SG11202002258WA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
MX2020003538A (es) Aglutinante anti-adrenomedulina (adm) para ser utilizado en terapia o prevencion de sintomas de padecimientos.
MX2020004698A (es) Exosomas que comprenden agentes terapeuticos de arn.
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
MY187540A (en) Compounds active towards bromodomains
MD3204025T2 (ro) Compoziții care conțin tulpini bacteriene
MD3206700T2 (ro) Compoziții conținând tulpini bacteriene
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
PH12019502002A1 (en) Combination theraphy
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2020004072A (es) Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
MX2020004014A (es) Sistema optimizado de protocolo de seguridad de cabecera.
PH12020550185A1 (en) Semaglutide in medical therapy
MX2019015167A (es) Farmacos antivirales.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
PH12016501938A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
MX2020004228A (es) Capa resistente al desgaste.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2018007408A (es) Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors